Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 1074.0 | 49 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 534.0 | 48 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 860.0 | 73 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 1016.0 | 56 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 929.0 | 39 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 914.0 | 67 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 1026.5 | 64 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 654.5 | 60 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 1196.0 | 47 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 1202.0 | 41 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | VEGF | 962.0 | 61 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 960.5 | 64 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 885.0 | 53 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 687.0 | 62 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1165.0 | 69 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 941.0 | 75 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 930.0 | 60 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1246.0 | 45 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1346.0 | 65 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1367.5 | 46 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1600.5 | 58 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1686.0 | 41 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | VEGF | 1326.0 | 65 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | VEGF | 955.0 | 55 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | VEGF | 994.0 | 63 |